3rd Annual Gene Therapy for Ophthalmic Disorders

Revolutionizing Genetic Therapy Development & Delivery to the Eye

Discovering Next Generation Administration Routes for the Eye; Overcoming the Translational Challenges of Ophthalmic Preclinical Models; & Discussing Toxicity & Targeting Challenges of Vector-Based Approaches

The ophthalmology field is bursting with novel genetic approaches for targeting many disorders, with gene therapy taking centre stage as a one-time treatment option. With more invasive subretinal approaches being used in the clinic, as well as more innovative outpatient methods such as suprachoroidal delivery, there are a lot of pros and cons to discuss as the field progresses towards developing efficacious and durable treatments for many ophthalmic disorders.

Returning for its 3rd year, the Gene Therapy for Ophthalmic Disorders is the definitive forum for those working on ophthalmic gene therapy. This is the only conference that unites pharma and biotech to address the most pressing challenges, with focus on discussing and sharing solutions with the key leaders in the industry.

This year we have expanded into two streams of learning, putting more emphasis on the individual challenges faced in both the preclinical and clinical phases of ophthalmic gene therapy drug development.

Gene therapy for ophthalmic disorders has only seen one FDA approved therapy, which drug will be the next? Join 150+ of your peers to discuss and overcome the barriers preventing drugs getting to market.

Leave the definitive 3rd Annual Gene Therapy for Ophthalmic Disorders forum equipped with knowledge of novel methods and developments, actionable lessons learned and new connections. Don’t miss your opportunity to be a part the conversation which could lead to the next drug approval.